Published: 12/08/2020 14:01 GMT (TPTX) - Turning Point Therapeutics Granted FDA Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With Ros1-positive Metastatic Non-small Cell Lung Cancer Who Have Not Been Treated With a Ros1 Tyrosine Kinase Inhibitor.
